Silexion Therapeutics is a pioneering developmental stage company dedicated to the development of innovative treatments for pancreatic cancer. The company conducted phase 2 clinical trial with its first generation product which has shown positive efficacy results vs the control of chemotherapy alone. Silexion’s commitment to pushing the boundaries of therapeutic advancements in the field of oncology, is focused in enhancing its first-generation product (LODERTM) to develop a new formulated product which will improve the clinical efficacy that Silexion observed with its first-generation product against pancreatic cancer. With a strong foundation in RNA interference technology, Silexion Therapeutics develops innovative RNA-based therapeutics designed to silence specific genes involved in pancreatic cancer growth and metastasis. By selectively suppressing these genes, it aims to disrupt tumor progression and enhance the therapeutic response.